About CANDEL THERAPEUTICS, INC.
Candel Therapeutics is a biotechnology company focused on developing off-the-shelf viral immunotherapies for solid tumors, with a lead therapy, aglatimagene besadenovec, showing significant clinical outcomes in prostate cancer. The company aims to extend and improve patients' lives through innovative immunotherapy without the toxicity of traditional treatments.
Development of off-the-shelf viral immunotherapiesEngineered viral platforms that activate the immune system to recognize and destroy cancer cellsClinical-stage investigational therapies for solid tumorsPhase 3 clinical trial data demonstrating meaningful outcomes for prostate cancerFDA Fast Track and RMAT Designation for lead therapy
Is this your company?
Claim this profile to keep it accurate — and see the federal & state opportunities GovIntel's AI has matched to CANDEL THERAPEUTICS, INC. right now.
Claim this profile See matched opportunitiesData compiled from public government sources including SAM.gov, USAspending.gov, and state procurement records. Last verified against federal award records. Inaccurate? Let us know.